MiMedx Group, Inc. MDXG 深 沪
等待开盘 04-02 09:30:00 美东时间
3.95
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 3.95
- 总市值 5.87亿
- 52周最高 7.99
- 市盈率 静 12.18
- 换手率 0.00%
- 52周最低 3.77
- 委 比 0.00%
- 总股本 1.49亿
- 历史最高 18.25
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.83
- 每 手 1
- 风险率 0.92%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多新浪财经ESG：MiMedx Group Inc. MSCI（明晟）ESG评级调降至B
新浪财经ESG评级中心提供包括资讯、报告、培训、咨询等在内的14项ESG服务，助力上市公司传播ESG理念，提升ESG可持续发展表现。点击查看【 ESG评级中...
03-25 07:00
MIMEDX Announces Launch of CHORIOFIX™
<p>MiMedx Group announced the commercial launch of CHORIOFIX, a new advanced wound care product. CHORIOFIX, a lyophilized human placental allograft, consists of two chorion layers with an intact intermediate layer, making it the company's thickest product to date. The product's structure enhances handling during positioning and suturing, and its uniform, dual-sided chorion configuration eliminates the need for orientation during application. Desi...
03-23 12:00
MiMedx Group Announces Commercial Launch Of AMNIOFIX Thyroid Shields, Product Line Extension Of AMNIOFIX DHACM Allografts
MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced the commercial launch of AMNIOFIX Thyroid Shields, a product line extension of the Company's AMNIOFIX dehydrated human amnion/chorion membrane
03-05 21:03
MIMEDX Expands Surgical Product Portfolio with the Launch of AMNIOFIX® Thyroid Shields
MiMedx Group has launched AMNIOFIX Thyroid Shields, a new allograft product designed for use in endocrine surgery. These shields are applied to the exposed Recurrent Laryngeal Nerve (RLN) and parathyroid glands after thyroidectomy to provide a protective barrier and support healing. The product, manufactured using MIMEDX's PURION® process, is preconfigured, easy to apply, and shelf-stable for up to five years. A study showed a 76% reduction in RL...
03-05 13:00
Earnings Scheduled For February 25, 2026
Companies Reporting Before The Bell • Clear Secure (NYSE:YOU) is expected to re...
02-25 19:11
What to Expect from MiMedx Group's Earnings
MiMedx Group (NASDAQ:MDXG) is set to give its latest quarterly earnings report ...
02-25 03:02
美股大行评级 | 大摩将康宁目标价从103美元升至127美元；潜在涨幅1779.7%！IGC Pharma获Ascendiant Capital升目标价至5美元
今日重点评级关注：Ascendiant Capital：维持IGC Pharma"买入"评级，目标价从4.75美元升至5美元；Brookline Capital：维持C4 Therapeutics"买入"评级，目标价从20美元升至30美元
02-24 10:27
Beyond The Numbers: 4 Analysts Discuss MiMedx Group Stock
4 analysts have expressed a variety of opinions on MiMedx Group (NASDAQ:MDXG) o...
02-23 20:00
美股大行评级 | 潜在涨幅1226.53%！RenovoRx获Ascendiant Capital升目标价至13美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持RenovoRx"买入"评级，目标价从12.5美元升至13美元；Lake Street：维持Insight Molecular"买入"评级，目标价从8美元升至12美元
02-18 16:48
Cantor Fitzgerald Maintains Overweight on MiMedx Group, Lowers Price Target to $8
Cantor Fitzgerald analyst Sarah James maintains MiMedx Group (NASDAQ:MDXG) with a Overweight and lowers the price target from $12 to $8.
02-17 23:28
